Melissa de los Reyes
AstraZeneca (Australia)(AU)AstraZeneca (Canada)(CA)
Publications by Year
Research Areas
Cancer Immunotherapy and Biomarkers, Lung Cancer Treatments and Mutations, Cytokine Signaling Pathways and Interactions, Head and Neck Cancer Studies, Cancer Genomics and Diagnostics
Most-Cited Works
- → Type I Interferon: Potential Therapeutic Target for Psoriasis?(2008)307 cited
- → Neutralization of interferon‐α/β–inducible genes and downstream effect in a phase I trial of an anti–interferon‐α monoclonal antibody in systemic lupus erythematosus(2009)279 cited
- → Regulation of Hemolysin Expression and Virulence of Staphylococcus aureus by a Serine/Threonine Kinase and Phosphatase(2010)167 cited
- → Development of Potential Pharmacodynamic and Diagnostic Markers for Anti-IFN-α Monoclonal Antibody Trials in Systemic Lupus Erythematosus(2008)132 cited
- → Regulation of CovR expression in Group B Streptococcus impacts blood–brain barrier penetration(2010)107 cited
- → Resistance to Durvalumab and Durvalumab plus Tremelimumab Is Associated with Functional STK11 Mutations in Patients with Non–Small Cell Lung Cancer and Is Reversed by STAT3 Knockdown(2021)80 cited
- → Serine/Threonine Phosphatase Stp1 Mediates Post-transcriptional Regulation of Hemolysin, Autolysis, and Virulence of Group B Streptococcus(2011)50 cited
- → PD-L1 + neutrophils contribute to injury-induced infection susceptibility(2021)45 cited
- → Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma(2022)40 cited
- → Tumor Mutational Burden as a Predictor of Survival with Durvalumab and/or Tremelimumab Treatment in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma(2023)29 cited